MRK - Merck & Co., Inc.
After hours:
| Previous Close | 110.32 |
| Open | 110.18 |
| Bid | 110.71 x 1100 |
| Ask | 111.10 x 900 |
| Day's Range | 109.02 - 111.51 |
| 52 Week Range | 83.05 - 119.65 |
| Volume | |
| Avg. Volume | 7,292,984 |
| Market Cap | 280.92B |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | 21.29 |
| EPS (TTM) | 5.20 |
| Earnings Date | Aug 01, 2023 |
| Forward Dividend & Yield | 2.92 (2.69%) |
| Ex-Dividend Date | Jun 14, 2023 |
| 1y Target Est | 124.42 |
- Reuters
UPDATE 1-US Chamber of Commerce sues over government's drug pricing power
The U.S. Chamber of Commerce on Friday sued the federal government, challenging a new law that for the first time gives Medicare the power to negotiate drug prices with pharmaceutical companies. In a complaint filed in federal court in Dayton, Ohio, the chamber said the pricing program violated drugmakers' due process rights under the U.S. Constitution by giving the government "unfettered discretion" to dictate maximum prices. It also said the program would impose exorbitant penalties on drugmakers that don't accept those prices, and amounted to an ultimatum: "agree to whatever price the government names, or we'll smash up your business."
- Reuters
US Chamber of Commerce sues over government's drug pricing power
The U.S. Chamber of Commerce on Friday sued the federal government, challenging a new law that for the first time gives Medicare the power to negotiate drug prices with pharmaceutical companies. In a complaint filed in federal court in Dayton, Ohio, the chamber said the pricing program violated drugmakers' due process rights under the U.S. Constitution by giving the government "unfettered discretion" to dictate maximum prices. It also said the program would impose exorbitant penalties on drugmakers that don't accept those prices, and amounted to an ultimatum: "agree to whatever price the government names, or we'll smash up your business."
Simply Wall St.Four Days Left To Buy Merck & Co., Inc. (NYSE:MRK) Before The Ex-Dividend Date
Merck & Co., Inc. ( NYSE:MRK ) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one business day...
ZacksMerck (MRK) Outpaces Stock Market Gains: What You Should Know
Merck (MRK) closed at $110.32 in the latest trading session, marking a +1.57% move from the prior day.
ZacksMerck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Business WireFDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
RAHWAY, N.J., June 08, 2023--FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
Motley FoolDrug Maker Merck Sues US Gov. Over Inflation Reduction Act
The war on drug prices faces a counter-offensive. While many pharmaceutical companies have been moaning and groaning about the new regulations on...
Yahoo Finance VideoMerck sues U.S. government over Medicare drug pricing negotiation
Merck is suing the U.S. government over a law that lets Medicare negotiate drug prices. Yahoo Finance health care reporter Anjalee Khemlani explains why Merck is upset over the law.
- Reuters
UPDATE 5-Merck sues US government to halt Medicare drug price negotiation
Merck & Co sued the U.S. government on Tuesday, seeking to halt the Medicare drug price negotiation program contained in the Inflation Reduction Act (IRA), which it argues violates the Fifth and First Amendments to the U.S. Constitution. This is the first attempt by a drugmaker to challenge the law, which the pharmaceutical industry says will result in a loss of profits that will force them to pull back on developing groundbreaking new treatments. The Biden administration's drug pricing reform aims to save $25 billion annually by 2031 through price negotiations for drugs paid for by Medicare, the government health plan for those age 65 and over.
ReutersMerck sues US government to halt Medicare drug price negotiation
Merck & Co said it sued the U.S. government on Tuesday, seeking an injunction of the drug price negotiation program contained in the Inflation Reduction Act (IRA), which it argues violates the Fifth and First Amendments to the U.S. Constitution.
Business WireU.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
RAHWAY, N.J., June 06, 2023--U.S. FDA Approves New Indication for Merck’s PREVYMIS® for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
Business WireMerck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
RAHWAY, N.J., June 06, 2023--Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
- Reuters
UPDATE 1-Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a mid-stage trial, the companies reported on Monday. With this and earlier data, Moderna is considering seeking faster approval from regulators for the treatment, the company told investors after having presented the results at the American Society of Clinical Oncology meeting in Chicago. "Some of the residual uncertainty seems to be going away on that potential (option)," said Moderna President Stephen Hoge.
ACCESSWIREModerna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced distant metastasis-free survival (DMFS) results from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA,
- Reuters
Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday. The results, presented at the American Society of Clinical Oncology meeting in Chicago, follow earlier promising data from the trial showing the customized mRNA vaccine given in combination with Merck's Keytruda cut the risk of death or recurrence of melanoma by 44% compared with Keytruda alone. The findings add to a growing body of evidence suggesting that mRNA technology, which rose to prominence during the COVID-19 pandemic, can be used to assemble personalized vaccines that train the immune system to attack the specific type of cancer cells in a patient's tumors.
Business WireMerck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
RAHWAY, N.J., June 03, 2023--KEYTRUDA Plus Chemo Before Surgery and as a Single Agent After Surgery Reduced Risk of EFS by 42% Vs Pre-Operative Chemo in Stage II, IIIA, IIIB NSCLC
Business WireKEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
RAHWAY, N.J. & KINGSTON, Ontario, June 03, 2023--KEYTRUDA Plus Chemo Significantly Improved Overall Survival Versus Chemo Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
Business WireFDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
RAHWAY, N.J., June 01, 2023--FDA Approves LYNPARZA Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated mCRPC
Business WireKEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
RAHWAY, N.J. & NUTLEY, N.J., May 25, 2023--KEYTRUDA® Plus LENVIMA® Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced RCC
ZacksInvestors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Business WireMerck Announces Third-Quarter 2023 Dividend
RAHWAY, N.J., May 23, 2023--Merck Announces Third-Quarter 2023 Dividend
Yahoo Finance VideoFed, labor market concerns showing 'some dents in the armor of the consumer': Strategist
Hennion & Walsh CIO Kevin Mahn joins Yahoo Finance Live to discuss the state of the consumer amid retail earnings, Target Q1 earnings, Walmart earnings preview, Fed rate hikes, inflation, and the impact on consumer spending.
BloombergDrugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data
(Bloomberg) -- European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma is closely watching.Most Read from BloombergHere’s How Much Wealth You Need to Join the Richest 1% GloballyMercedes Sets Out to Make Sexy Vans With Yacht-Like InteriorsJPMorgan Asset Says Markets Are Right to Bet on US Rate CutsDebt-Limit Talks to Intensify as Biden Set to Depart for JapanSeveral major drugmakers keen to expand in immunology have been studying the $23 bi
Business WireMerck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
RAHWAY, N.J., May 15, 2023--Merck ASCO Curtain Raiser
ZacksThe Zacks Analyst Blog Highlights UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International
UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International are part of the Zacks top Analyst Blog.
